STAAR Surgical Company (NASDAQ: STAA) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.42 | Insider Own | 35.10% | Shs Outstand | 49.79M | Perf Week | 4.19% |
| Market Cap | 1.21B | Forward P/E | 25.43 | EPS next Y | 0.96 | Insider Trans | 3.84% | Shs Float | 49.39M | Perf Month | -13.46% |
| Enterprise Value | 1.12B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 10.31% | Perf Quarter | -7.59% |
| Income | -20.98M | P/S | 4.18 | EPS this Y | 270.01% | Inst Trans | - | Short Ratio | 6.26 | Perf Half Y | 28.62% |
| Sales | 290.38M | P/B | 3.45 | EPS next Y | 34.13% | ROA | -4.66% | Short Interest | 5.09M | Perf YTD | 5.50% |
| Book/sh | - | P/C | - | EPS next 5Y | 27.38% | ROE | -6.07% | 52W High | 35.84 -32.09% | Perf Year | 34.59% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -1.26% | 52W Low | 15.58 56.25% | Perf 3Y | -56.52% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -5.59% 7.95% | Gross Margin | 76.43% | Volatility | 5.51% 5.45% | Perf 5Y | -81.53% |
| Dividend TTM | - | EV/Sales | 3.85 | EPS Y/Y TTM | -2.44% | Oper. Margin | -1.72% | ATR (14) | 1.42 | Perf 10Y | 276.51% |
| Dividend Ex-Date | - | Quick Ratio | 4.31 | Sales Y/Y TTM | -7.32% | Profit Margin | -7.24% | RSI (14) | 41.03 | Recom | 2.80 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.12 | EPS Q/Q | 173.08% | SMA20 | -5.47% | Beta | 1.25 | Target Price | 32.60 |
| Payout | 0.00% | Debt/Eq | 0.11 | Sales Q/Q | 118.60% | SMA50 | -13.38% | Rel Volume | 1.51 | Prev Close | 24.36 |
| Employees | 1,157 | LT Debt/Eq | 0.09 | Earnings | Aug 12 | SMA200 | 0.10% | Avg Volume | 895.43K | Price | 24.34 |
| IPO Date | Feb 24, 1992 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 600.84% 18.81% | Net Debt/EBITDA | 23.03 | Volume | 1,353,648 | Change | -0.08% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-14-26 | Reiterated | Stifel Nicolaus | $18 → $31 | |
| May-14-26 | Upgrade | Wedbush | Neutral → Outperform | $26 → $40 |
| May-14-26 | Reiterated | Canaccord Genuity | Buy | $27 → $32 |
| May-14-26 | Reiterated | Mizuho | Neutral | $27 |
| May-14-26 | Reiterated | Piper Sandler | Neutral | $33 |
| Apr-09-26 | Upgrade | Canaccord Genuity | Hold → Buy | $22 → $27 |
| Mar-04-26 | Reiterated | Stifel Nicolaus | $19 → $18 | |
| Feb-09-26 | Reiterated | Stifel Nicolaus | $28 → $19 | |
| Feb-03-26 | Initiated | Wedbush | Neutral | $26 |
| Jan-16-26 | Resumed | Morgan Stanley | Underweight | $13 |
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 1/2/2026 | FY 2024 12/27/2024 | FY 2023 12/29/2023 | FY 2022 12/30/2022 | FY 2021 12/31/2021 | FY 2020 1/1/2021 | FY 2019 1/3/2020 | FY 2018 12/28/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 291 | 239 | 314 | 322 | 284 | 230 | 163 | 150 | 124 | |
| Cost of Goods Sold Incl. D&A | 69 | 57 | 74 | 70 | 61 | 52 | 45 | 38 | 32 | |
| Gross Profit | 223 | 182 | 240 | 253 | 223 | 179 | 118 | 112 | 92 | |
| Selling, General and Administrative Excl. Other | 176 | 188 | 198 | 180 | 144 | 111 | 80 | 75 | 63 | |
| Research and Development | 38 | 40 | 54 | 44 | 36 | 34 | 32 | 25 | 22 | |
| Other Operating Expense | 13 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | -6 | -46 | -13 | 28 | 44 | 33 | 7 | 12 | 7 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -15 | -36 | 4 | 6 | 2 | -2 | 1 | 1 | 0 | |
| Net Income Before Taxes | -20 | -82 | -9 | 34 | 46 | 31 | 8 | 13 | 7 | |
| Income Taxes | 2 | -2 | 11 | 12 | 6 | 4 | 2 | -1 | 2 | |
| Consolidated Net Income | -21 | -80 | -20 | 21 | 40 | 28 | 6 | 14 | 5 | |
| Net Income From Continuing Operations | -21 | -80 | -20 | 21 | 40 | 28 | 6 | 14 | 5 | |
| Net Income | -21 | -80 | -20 | 21 | 40 | 28 | 6 | 14 | 5 | |
| EPS (Recurring) | -0.42 | -1.62 | -0.41 | 0.44 | 0.83 | 0.52 | 0.13 | 0.32 | 0.11 | |
| EPS (Basic, Before Extraordinaries) | -0.42 | -1.62 | -0.41 | 0.44 | 0.83 | 0.52 | 0.13 | 0.32 | 0.11 | |
| EPS (Diluted) | -0.42 | -1.62 | -0.41 | 0.43 | 0.80 | 0.50 | 0.12 | 0.30 | 0.11 | |
| EBITDA | -5 | -74 | -2 | 39 | 50 | 35 | 10 | 16 | 9 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | 72.58 | 60.68 | 182.60 | 660.17 | 114.60 | 284.18 | |
| Price To Sales Ratio | 4.18 | 4.94 | 3.78 | 4.75 | 8.20 | 18.66 | 22.36 | 10.08 | 11.34 | |
| Gross Margin | 76.63 | 76.15 | 76.43 | 78.57 | 78.52 | 77.83 | 72.39 | 74.67 | 74.19 | |
| Operating Margin | -2.06 | -19.25 | -4.14 | 8.70 | 15.49 | 14.35 | 4.29 | 8.00 | 5.65 | |
| Net Margin | -7.22 | -33.47 | -6.37 | 6.52 | 14.08 | 12.17 | 3.68 | 9.33 | 4.03 | |
| Shares Outstanding | 50 | 50 | 49 | 49 | 48 | 47 | 46 | 44 | 45 | |
| Market Capitalization | 1,217 | 1,180 | 1,186 | 1,529 | 2,330 | 4,291 | 3,644 | 1,513 | 1,407 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Butcher Arthur C | Director | Jun 18 '26 | Option Exercise | 0.00 | 5,341 | 0 | 9,549 | Jun 22 |
| SILVERMAN LOU | Director | Jun 18 '26 | Option Exercise | 0.00 | 10,683 | 0 | 11,158 | Jun 22 |
| Jiang Wei | Director | Jun 18 '26 | Option Exercise | 0.00 | 10,683 | 0 | 77,127 | Jun 22 |
| Foust Warren | Interim Co-CEO and Pres. & COO | May 15 '26 | Option Exercise | 0.00 | 32,990 | 0 | 32,990 | May 19 |
| Michna Magda | Chief Development Officer | May 15 '26 | Option Exercise | 0.00 | 19,795 | 0 | 19,795 | May 19 |
| ANDREWS DEBORAH J | Interim Co-CEO and CFO | May 15 '26 | Option Exercise | 0.00 | 15,699 | 0 | 15,699 | May 19 |
| Michna Magda | Chief Development Officer | Mar 14 '26 | Option Exercise | 0.00 | 17,595 | 0 | 36,001 | Mar 16 |
| Foust Warren | Interim Co-CEO and Pres. & COO | Mar 14 '26 | Option Exercise | 0.00 | 29,325 | 0 | 63,588 | Mar 16 |
| Foust Warren | Interim Co-CEO and Pres. & COO | Mar 12 '26 | Option Exercise | 0.00 | 8,175 | 0 | 34,263 | Mar 16 |
| Michna Magda | Chief Development Officer | Mar 12 '26 | Option Exercise | 0.00 | 6,178 | 0 | 20,622 | Mar 16 |
| BROADWOOD PARTNERS, L.P. | director, 10 percent owner: | Mar 13 '26 | Buy | 18.61 | 316,017 | 5,882,656 | 16,123,842 | Mar 13 |
| BROADWOOD PARTNERS, L.P. | director, 10 percent owner: | Mar 12 '26 | Buy | 18.12 | 299,432 | 5,424,330 | 15,807,825 | Mar 13 |
| BROADWOOD PARTNERS, L.P. | director, 10 percent owner: | Mar 11 '26 | Buy | 17.52 | 54,764 | 959,558 | 15,508,393 | Mar 13 |
| Jiang Wei | Director | Jan 12 '26 | Option Exercise | 0.00 | 20,967 | 0 | 66,444 | Jan 14 |
| BROADWOOD PARTNERS, L.P. | 10% Owner | Jan 09 '26 | Buy | 22.05 | 27,485 | 606,138 | 15,453,629 | Jan 13 |